NOTICE: Labnodes now supports vumc.org email addresses. If your email changed, please update your profile today.
  1. Acute blockade of the Caenorhabditis elegans dopamine transporter DAT-1 by the mammalian norepinephrine transporter inhibitor nisoxetine reveals the influence of genetic modifications of dopamine signaling in vivo. Bermingham DP, Hardaway JA, Snarrenberg CL, Robinson SB, Folkes OM, Salimando GJ, Jinnah H, Blakely RD (2016) Neurochem Int : 122-8
    › Primary publication · 26850478 (PubMed) · PMC4969213 (PubMed Central)
  2. Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter. Bollinger SR, Engers DW, Ennis EA, Wright J, Locuson CW, Lindsley CW, Blakely RD, Hopkins CR (2015) Bioorg Med Chem Lett 25(8): 1757-1760
    › Primary publication · 25801932 (PubMed) · PMC4385452 (PubMed Central)
  3. Single-quantum-dot tracking reveals altered membrane dynamics of an attention-deficit/hyperactivity-disorder-derived dopamine transporter coding variant. Kovtun O, Sakrikar D, Tomlinson ID, Chang JC, Arzeta-Ferrer X, Blakely RD, Rosenthal SJ (2015) ACS Chem Neurosci 6(4): 526-34
    › Primary publication · 25747272 (PubMed) · PMC5530757 (PubMed Central)
  4. Physical Interactions and Functional Relationships of Neuroligin 2 and Midbrain Serotonin Transporters. Ye R, Quinlan MA, Iwamoto H, Wu HH, Green NH, Jetter CS, McMahon DG, Veestra-VanderWeele J, Levitt P, Blakely RD (2015) Front Synaptic Neurosci : 20
    › Primary publication · 26793096 (PubMed) · PMC4707279 (PubMed Central)
  5. Identification and characterization of ML352: a novel, noncompetitive inhibitor of the presynaptic choline transporter. Ennis EA, Wright J, Retzlaff CL, McManus OB, Lin Z, Huang X, Wu M, Li M, Daniels JS, Lindsley CW, Hopkins CR, Blakely RD (2015) ACS Chem Neurosci 6(3): 417-27
    › Primary publication · 25560927 (PubMed) · PMC4367188 (PubMed Central)
  6. Glial Expression of the Caenorhabditis elegans Gene swip-10 Supports Glutamate Dependent Control of Extrasynaptic Dopamine Signaling. Hardaway JA, Sturgeon SM, Snarrenberg CL, Li Z, Xu XZ, Bermingham DP, Odiase P, Spencer WC, Miller DM, Carvelli L, Hardie SL, Blakely RD (2015) J Neurosci 35(25): 9409-23
    › Primary publication · 26109664 (PubMed) · PMC4478255 (PubMed Central)
  7. Genetic variation in alpha2-adrenoreceptors and heart rate recovery after exercise. Kohli U, Diedrich A, Kannankeril PJ, Muszkat M, Sofowora GG, Hahn MK, English BA, Blakely RD, Stein CM, Kurnik D (2015) Physiol Genomics 47(9): 400-6
    › Primary publication · 26058836 (PubMed) · PMC4556937 (PubMed Central)
  8. Disruption of Transient Serotonin Accumulation by Non-Serotonin-Producing Neurons Impairs Cortical Map Development. Chen X, Ye R, Gargus JJ, Blakely RD, Dobrenis K, Sze JY (2015) Cell Rep
    › Primary publication · 25600870 (PubMed) · PMC4824665 (PubMed Central)
  9. Clustering autism: using neuroanatomical differences in 26 mouse models to gain insight into the heterogeneity. Ellegood J, Anagnostou E, Babineau BA, Crawley JN, Lin L, Genestine M, DiCicco-Bloom E, Lai JK, Foster JA, Peñagarikano O, Geschwind DH, Pacey LK, Hampson DR, Laliberté CL, Mills AA, Tam E, Osborne LR, Kouser M, Espinosa-Becerra F, Xuan Z, Powell CM, Raznahan A, Robins DM, Nakai N, Nakatani J, Takumi T, van Eede MC, Kerr TM, Muller C, Blakely RD, Veenstra-VanderWeele J, Henkelman RM, Lerch JP (2015) Mol Psychiatry 20(1): 118-25
    › Primary publication · 25199916 (PubMed) · PMC4426202 (PubMed Central)
  10. Cholinergic capacity mediates prefrontal engagement during challenges to attention: evidence from imaging genetics. Berry AS, Blakely RD, Sarter M, Lustig C (2015) Neuroimage : 386-95
    › Primary publication · 25536497 (PubMed) · PMC4469545 (PubMed Central)